Lisa Olson - Sep 14, 2021 Form 4 Insider Report for Magenta Therapeutics, Inc. (DNTH)

Role
Head of Research and Chief Scientific Officer
Signature
/s/ Lisa Olson
Stock symbol
DNTH
Transactions as of
Sep 14, 2021
Transactions value $
$0
Form type
4
Date filed
9/16/2021, 07:43 PM
Previous filing
Aug 3, 2021
Next filing
Sep 20, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNTH Common Stock Award $0 +20K $0.00 20K Sep 14, 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 11, 2021, the reporting person was granted 40,000 restricted stock units. The restricted stock units vest in two equal installments subject to the achievement of certain performance milestones related to the issuer's business plans. The first performance milestone was achieved, resulting in vesting of 20,000 restricted stock units and the corresponding issuance of 20,000 shares of issuer common stock.

Remarks:

Head of Research and Chief Scientific Officer